Evidence map›Paper›PMID 23637009›Full record

ReviewCurrent rheumatology reports2013

Vaccination and inflammatory arthritis: overview of current vaccines and recommended uses in rheumatology.

Claudia Müller-Ladner, Ulf Müller-Ladner

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Infections in the era of immunobiologicals.Anais brasileiros de dermatologia
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Claudia Müller-LadnerDepartment of Clinical Immunology and Rheumatology Kerckhoff Clinic Bad Nauheim, Justus-Liebig-University Giessen, Benekestrasse 2, 61231, Bad Nauheim, Germany.
Ulf Müller-Ladner

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with autoimmune inflammatory rheumatic diseases are prone to infectious complications during the course of their disease. The underlying disease with an impaired immune system and additional different immunosuppressive medication render patients more susceptible to infections, some of which are potentially preventable with vaccination. Since it is not clear how strongly the underlying and medication-induced immunosuppression interferes with vaccination, a lot of questions remain about its indications, efficacy and safety . Due to these unresolved questions, in 2011, EULAR published general guidelines about vaccination in patients with autoimmune rheumatic diseases. These guidelines provide a basis for patient care and are also the basis of the following review article. With more available and earlier used immunosuppressive medications, a lot of questions still remain about optimal use of vaccines, the role of different medication combinations on efficacy and safety of vaccinations especially of the actual prevention of disease, the role of age, gender, disease activity and duration, and optimal revaccination schedules in this patient group. Actual studies elute the role of different medication combinations on efficacy and safety mainly addressing influenza and pneumococcal vaccination. In addition, interesting new data on basic immunological processes during TNF-α-blockade open up questions for further research.

Indexed as

VaccinationArthritisContraindicationsFemaleHumansImmunocompromised HostImmunosuppressive AgentsInfluenza, HumanInfluenza VaccinesMalePneumococcal InfectionsPneumococcal VaccinesPractice Guidelines as TopicRheumatologyVaccines, AttenuatedImmunosuppressive AgentsInfluenza VaccinesPneumococcal VaccinesVaccines, Attenuated

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.